|
1
|
Lordick F, Allum W, Carneiro F, Mitry E,
Tabernero J, Tan P, Van Cutsem E, van de Velde C and Cervantes A:
Unmet needs and challenges in gastric cancer: The way forward.
Cancer Treat Rev. 40:692–700. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Noh SH, Park SR, Yang HK, Chung HC, Chung
IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, et al: Adjuvant
capecitabine plus oxaliplatin for gastric cancer after D2
gastrectomy (CLASSIC): 5-year follow-up of an open-label,
randomised phase 3 trial. Lancet Oncol. 15:1389–1396. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bradshaw AD and Sage EH: SPARC, a
matricellular protein that functions in cellular differentiation
and tissue response to injury. J Clin Invest. 107:1049–1054. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yin J, Chen G, Liu Y, Liu S, Wang P, Wan
Y, Wang X, Zhu J and Gao H: Downregulation of SPARC expression
decreases gastric cancer cellular invasion and survival. J Exp Clin
Cancer Res. 29:592010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang J, Wang P, Zhu J, Wang W, Yin J,
Zhang C, Chen Z, Sun L, Wan Y, Wang X, et al: SPARC expression is
negatively correlated with clinicopathological factors of gastric
cancer and inhibits malignancy of gastric cancer cells. Oncol Rep.
31:2312–2320. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brekken RA and Sage EH: SPARC, a
matricellular protein: At the crossroads of cell-matrix
communication. Matrix Biol. 19:816–827. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rivera LB, Bradshaw AD and Brekken RA: The
regulatory function of SPARC in vascular biology. Cell Mol Life
Sci. 68:3165–3173. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nakashima S, Kobayashi S, Sakai D,
Tomokuni A, Tomimaru Y, Hama N, Wada H, Kawamoto K, Marubashi S,
Eguchi H, et al: Prognostic impact of tumoral and/or peri-tumoral
stromal SPARC expressions after surgery in patients with biliary
tract cancer. J Surg Oncol. 110:1016–1022. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nagai MA, Gerhard R, Fregnani JH, Nonogaki
S, Rierger RB, Netto MM and Soares FA: Prognostic value of NDRG1
and SPARC protein expression in breast cancer patients. Breast
Cancer Res Treat. 126:1–14. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mantoni TS, Schendel RR, Rödel F,
Niedobitek G, Al-Assar O, Masamune A and Brunner TB: Stromal SPARC
expression and patient survival after chemoradiation for
non-resectable pancreatic adenocarcinoma. Cancer Biol Ther.
7:1806–1815. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yamashita K, Upadhay S, Mimori K, Inoue H
and Mori M: Clinical significance of secreted protein acidic and
rich in cystein in esophageal carcinoma and its relation to
carcinoma progression. Cancer. 97:2412–2419. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang HY, Li YY, Shao Q, Hou JH, Wang F,
Cai MB, Zeng YX and Shao JY: Secreted protein acidic and rich in
cysteine (SPARC) is associated with nasopharyngeal carcinoma
metastasis and poor prognosis. J Transl Med. 10:272012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chew A, Salama P, Robbshaw A, Klopcic B,
Zeps N, Platell C and Lawrance IC: SPARC, FOXP3, CD8 and CD45
correlation with disease recurrence and long-term disease-free
survival in colorectal cancer. PLoS One. 6:e220472011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Von Hoff DD, Ramanathan RK, Borad MJ,
Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias
JL, et al: Gemcitabine plus nab-paclitaxel is an active regimen in
patients with advanced pancreatic cancer: A phase I/II trial. J
Clin Oncol. 29:4548–4554. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Takeno A, Takemasa I, Doki Y, Yamasaki M,
Miyata H, Takiguchi S, Fujiwara Y, Matsubara K and Monden M:
Integrative approach for differentially overexpressed genes in
gastric cancer by combining large-scale gene expression profiling
and network analysis. Br J Cancer. 99:1307–1315. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tai IT, Dai M, Owen DA and Chen LB:
Genome-wide expression analysis of therapy-resistant tumors reveals
SPARC as a novel target for cancer therapy. J Clin Invest.
115:1492–1502. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gao YY, Han RB, Wang X, Ge SH, Li HL, Deng
T, Liu R, Bai M, Zhou LK, Zhang XY, et al: Change of SPARC
expression after chemotherapy in gastric cancer. Cancer Biol Med.
12:33–40. 2015.PubMed/NCBI
|
|
18
|
Inoue M, Senju S, Hirata S, Ikuta Y,
Hayashida Y, Irie A, Harao M, Imai K, Tomita Y, Tsunoda T, et al:
Identification of SPARC as a candidate target antigen for
immunotherapy of various cancers. Int J Cancer. 127:1393–1403.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao ZS, Wang YY, Chu YQ, Ye ZY and Tao
HQ: SPARC is associated with gastric cancer progression and poor
survival of patients. Clin Cancer Res. 16:260–268. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang JL, Chen GW, Liu YC, Wang PY, Wang
X, Wan YL, Zhu J, Gao HQ, Yin J, Wang W and Tian ML: Secreted
protein acidic and rich in cysteine (SPARC) suppresses angiogenesis
by down-regulating the expression of VEGF and MMP-7 in gastric
cancer. PLoS One. 7:e446182012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee HE, Park KU, Yoo SB, Nam SK, Park DJ,
Kim HH and Lee HS: Clinical significance of intratumoral HER2
heterogeneity in gastric cancer. Eur J Cancer. 49:1448–1457. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jeung HC, Rha SY, Im CK, Shin SJ, Ahn JB,
Yang WI, Roh JK, Noh SH and Chung HC: A randomized phase 2 study of
docetaxel and S-1 versus docetaxel and cisplatin in advanced
gastric cancer with an evaluation of SPARC expression for
personalized therapy. Cancer. 117:2050–2057. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang CS, Lin KH, Chen SL, Chan YF and
Hsueh S: Overexpression of SPARC gene in human gastric carcinoma
and its clinic-pathologic significance. Br J Cancer. 91:1924–1930.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Franke K, Carl-McGrath S, Röhl FW,
Lendeckel U, Ebert MP, Tänzer M, Pross M and Röcken C: Differential
expression of SPARC in intestinal-type gastric cancer correlates
with tumor progression and nodal spread. Transl Oncol. 2:310–320.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maeng HY, Song SB, Choi DK, Kim KE, Jeong
HY, Sakaki Y and Furihata C: Osteonectin-expressing cells in human
stomach cancer and their possible clinical significance. Cancer
Lett. 184:117–121. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang L, Yang M, Shan L, Qi L, Chai C, Zhou
Q, Yao K, Wu H and Sun W: The role of SPARC protein expression in
the progress of gastric cancer. Pathol Oncol Res. 18:697–702. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Quante M, Tu SP, Tomita H, Gonda T, Wang
SS, Takashi S, Baik GH, Shibata W, Diprete B, Betz KS, et al: Bone
marrow-derived myofibroblasts contribute to the mesenchymal stem
cell niche and promote tumor growth. Cancer Cell. 19:257–272. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang L, Sah B, Ma J, Shang C, Huang Z and
Chen Y: A prospective, randomized, controlled, trial comparing
occult-scar incision laparoscopic cholecystectomy and classic
three-port laparoscopic cholecystectomy. Surg Endosc. 28:1131–1135.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Puolakkainen PA, Brekken RA, Muneer S and
Sage EH: Enhanced growth of pancreatic tumors in SPARC-null mice is
associated with decreased deposition of extracellular matrix and
reduced tumor cell apoptosis. Mol Cancer Res. 2:215–224.
2004.PubMed/NCBI
|
|
30
|
Sinn M, Sinn BV, Striefler JK, Lindner JL,
Stieler JM, Lohneis P, Bischoff S, Bläker H, Pelzer U, Bahra M, et
al: SPARC expression in resected pancreatic cancer patients treated
with gemcitabine: Results from the CONKO-001 study. Ann Oncol.
25:1025–1032. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Desai N, Trieu V, Damascelli B and
Soon-Shiong P: SPARC expression correlates with tumor response to
albumin-bound paclitaxel in head and neck cancer patients. Transl
Oncol. 2:59–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hidalgo M, Plaza C, Musteanu M, Illei P,
Brachmann CB, Heise C, Pierce D, Lopez-Casas PP, Menendez C,
Tabernero J, et al: SPARC expression did not predict efficacy of
nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic
pancreatic cancer in an exploratory analysis of the phase III MPACT
trial. Clin Cancer Res. 21:4811–4818. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schneeweiss A, Seitz J, Smetanay K,
Schuetz F, Jaeger D, Bachinger A, Zorn M, Sinn HP and Marmé F:
Efficacy of nab-paclitaxel does not seem to be associated with
SPARC expression in metastatic breast cancer. Anticancer Res.
34:6609–6615. 2014.PubMed/NCBI
|
